Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superiority reg...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Diabetes Investig
Main Authors: Cho, Kyu Yong, Nakamura, Akinobu, Omori, Kazuno, Takase, Takahiro, Miya, Aika, Yamamoto, Kohei, Nomoto, Hiroshi, Kameda, Hiraku, Taneda, Shinji, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264405/
https://ncbi.nlm.nih.gov/pubmed/33131199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13457
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker